Treatment Action Group (TAG) welcomes and celebrates the U.S. Food and Drug Administration’s (FDA) approval of Apretude brand cabotegravir, the first injectable medication for use as pre-exposure prophylaxis (PrEP) to reduce the risk of HIV transmission.
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.
December 2021 Update, June 2022: The purported researcher responsible for the experiment described in this film, Serhat Gumrukcu, was indicted for murder-for-hire at the end of May 2022. The case is ongoing. In parallel, two independent investigations by financial media…
To commemorate the 33rd World AIDS Day, on December 1, 2021, Treatment Action Group in collaboration with the HIV Vaccine Trials Network, Southern AIDS Coalition, and Black AIDS Institute held this webinar to reflect on the past and celebrate the many successes and innovations in biomedical research.
November 2021 Examples of media coverage: Scientists report finding a second person to be ‘naturally’ cured of HIV, raising hopes for future treatments - Megan Molteni, STAT News, November 15, 2021 A Second Woman May Be Naturally Cured of HIV…
November 2021 Examples of media coverage: Research team develops vaccine that kills HIV in monkeys - The Asahi Shimbun, November 9, 2021 A New Vaccine Kills HIV in Monkeys. And It's Coming to Humans in 5 Years - Interesting Engineering,…
Developing an HIV vaccine is a difficult scientific challenge, but remains a critical priority. This handout provides an update on HIV vaccine research and a summary of results from the efficacy trials that have been conducted to date, and it…
Treatment Action Group (TAG) recognizes the importance of intentionally engaging the community broadly in our advocacy efforts, and we believe that the community should always be at the forefront of advocacy and research. Meaningful community engagement builds trust and fosters…
HIV advocacy laid the foundation for much of the work we do today. This handout was developed in collaboration with the Black AIDS Institute, HIV Vaccine Trials Network, and Southern AIDS Coalition. The handout provides a summary of the history…
HIV prevention research continues to rapidly evolve. The availability of pre-exposure prophylaxis (PrEP) has necessitated the development of new approaches to testing the efficacy of additional biomedical HIV prevention options. This handout was developed in collaboration with the Black AIDS…